Navigation Links
Eqalix Enters Sponsored Research Agreement with Temple University
Date:12/11/2012

Reston, VA (PRWEB) December 11, 2012

Under the agreement, Eqalix and Temple Bioengineering Chair and Professor Peter I. Lelkes will jointly advance the development of its three breakthrough technologies for regenerative medicine – protein-based skin substitute, regenerative blood vessels and nerve endings and regeneration of damaged and traumatized organs.

“This arrangement with Temple University works well with our strategy as an emerging company to maintain low overhead costs while accessing leading scientific expertise for the development of our product candidates,” said Eqalix Chairman and CEO Joseph P. Connell. “At the same time, we are building another example of a collaborative effort between the private sector and academia to further the development of novel approaches to treat diseases requiring improved therapies that will address the unmet needs of patients.”

Eqalix is an emerging regenerative medicine development company with a goal of enhancing the quality of life of consumers and patients by providing novel nano-materials for the repair and regeneration of diseased, traumatized and aging tissues. Its innovative technologies are intended to revolutionize the unmet needs in multiple commercial and therapeutic applications in the Regenerative Medicine space.

“We are excited and enthusiastic about entering into a Sponsored Research Agreement with a visionary start-up company such as Eqalix that will entail groundbreaking research in regenerative engineering, as well as the development of innovative and affordable products for wound care and cosmetic applications alike,” said Lelkes, who also serves as director of the Institute for Regenerative Medicine and Engineering in Temple’s School of Medicine.

Eqalix has received exclusive commercial licensing from other Philadelphia institutions for several groundbreaking technologies being developed in the fields of aesthetic dermatology, the consumer market for beauty and skin care, acute and chronic wounds requiring skin replacement, vascular replacements and the repair of traumatic damage to peripheral nerves.

Eqalix plans to leverage these technologies to develop and commercialize: a) plant protein-based nano-fiber scaffolds for use in aesthetic dermatology and wound healing markets; b) small-diameter hybrid vessels that reduce graft thrombogenicity and promote the creation of a functional endothelium after implantation; and c) three-dimensional tissue scaffolds with tunable properties for tissue and organ replacement and repair.

The technologies move the bar higher and intend to replicate the function of damaged, diseased or aging tissues by providing “implants” or scaffolds that are non-immunogenic, bio-compatible, and intended to restore the features and function of the damaged tissue by using the body’s own repair mechanisms. Eqalix is attempting to create skin without scarring and contraction, blood vessels without clotting, repair of injured nerves and organ beyond current capabilities.

“These lofty goals, although seemingly futuristic, are in the immediate realm of scientific possibilities today --- and at Eqalix,” said Connell.

Temple’s new bioengineering department was established in January 2012. Housed in the College of Engineering, Temple’s fastest growing college, the department seeks to provide a well-rounded, in-depth education and a world-class research experience at the interface of engineering, the life sciences and medicine, with the goal of promoting scientific discovery, as well as the development of new technologies that will benefit humanity.

Eqalix, Inc. is a privately held Virginia based C-Corporation located in Reston, VA.
Contact: Joseph P. Connell, 910-233-0806; jconnell (at) eqalix (dot) com

Read the full story at http://www.prweb.com/releases/2012/12/prweb10213704.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
2. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
3. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
4. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
5. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
6. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
7. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
8. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
9. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
10. Wolters Kluwer Research Now Available via Bloomberg Tradebook
11. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):